Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of induction TPF followed by radiotherapy plus cetuximab versus concurrent chemoradiotherapy in unresectable locally advanced head and neck squamous cell carcinoma
2008-005760-14Phase 3Completed
- Sponsor
- GORTEC
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab, docetaxel, cisplatin and fluorouracil in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GORTEC. Primary endpoint: Progression-free survival at 3 years. Started Mar 2009; status: completed.
02
Drugs
cetuximabdocetaxelcisplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2008-005760-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005760-14.